Toll Free: 1-888-928-9744
Published: Aug, 2016 | Pages:
90 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Scar - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Scar - Pipeline Review, H2 2016', provides an overview of the Scar pipeline landscape. The report provides comprehensive information on the therapeutics under development for Scar, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Scar and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Scar - The report reviews pipeline therapeutics for Scar by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Scar therapeutics and enlists all their major and minor projects - The report assesses Scar therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Scar Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Scar - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Scar pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table Of Content
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Scar Overview 9 Therapeutics Development 10 Pipeline Products for Scar - Overview 10 Pipeline Products for Scar - Comparative Analysis 11 Scar - Therapeutics under Development by Companies 12 Scar - Therapeutics under Investigation by Universities/Institutes 14 Scar - Pipeline Products Glance 15 Late Stage Products 15 Clinical Stage Products 16 Early Stage Products 17 Scar - Products under Development by Companies 18 Scar - Products under Investigation by Universities/Institutes 19 Scar - Companies Involved in Therapeutics Development 20 3M Drug Delivery Systems 20 Albireo AB 21 Altacor Limited 22 Beech Tree Labs, Inc. 23 Clanotech AB 24 Escape Therapeutics, Inc. 25 FirstString Research, Inc. 26 LegoChem Biosciences, Inc 27 Moerae Matrix, Inc. 28 Promore Pharma 29 RXi Pharmaceuticals Corporation 30 VBS Pharmaceuticals 31 Scar - Therapeutics Assessment 32 Assessment by Monotherapy Products 32 Assessment by Target 33 Assessment by Mechanism of Action 35 Assessment by Route of Administration 37 Assessment by Molecule Type 39 Drug Profiles 41 A-3914 - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 A-5425 - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 BTL-slo - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 CLT-28643 - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 decorin - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 Drug to Agonize Beta 2 Receptor for Wound Scars - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 FibroStem - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 FS-2 - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 Granexin - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 ICX-RHY - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 LCB-030110 - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 MG-53 - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 MMI-0100 - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 Monoclonal Antibody to Inhibit LRG1 for AMD, Diabetic Retinopathy, Oncology and Scar - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 nefopam hydrochloride - Drug Profile 59 Product Description 59 Mechanism Of Action 59 R&D Progress 59 OLX-101 - Drug Profile 60 Product Description 60 Mechanism Of Action 60 R&D Progress 60 Polysaccharide for Wounds and Scars - Drug Profile 61 Product Description 61 Mechanism Of Action 61 R&D Progress 61 PXL-01 - Drug Profile 62 Product Description 62 Mechanism Of Action 62 R&D Progress 62 Recombinant Protein for Immunology, Dermatology, Oncology and Musculoskeletal Disorders - Drug Profile 64 Product Description 64 Mechanism Of Action 64 R&D Progress 64 Recombinant Protein for Scar - Drug Profile 65 Product Description 65 Mechanism Of Action 65 R&D Progress 65 RXI-109 - Drug Profile 66 Product Description 66 Mechanism Of Action 66 R&D Progress 66 S-34240 - Drug Profile 72 Product Description 72 Mechanism Of Action 72 R&D Progress 72 Synthetic Peptides to Antagonize TGF-Beta Receptor for Diabetic Foot Ulcers, Pulmonary Fibrosis and Dermatology - Drug Profile 73 Product Description 73 Mechanism Of Action 73 R&D Progress 73 tranilast - Drug Profile 75 Product Description 75 Mechanism Of Action 75 R&D Progress 75 Scar - Dormant Projects 76 Scar - Discontinued Products 77 Scar - Product Development Milestones 78 Featured News & Press Releases 78 Aug 18, 2016: ScarX announces approval for trial of first clinically-promising scar reduction cream 78 Apr 28, 2016: RXi Pharmaceuticals Announces Advancement of its Ophthalmology Franchise with Successful Topical Delivery of sd-rxRNA to the Cornea in an in vivo Corneal Wound Model 79 Apr 25, 2016: RXi Pharmaceuticals to Present at 18th Annual TIDES: Oligonucleotide and Peptides Therapeutics Conference 80 Apr 19, 2016: RXi Pharmaceuticals Fortifies its Novel RNAi Patent Portfolio with Notice of Allowance for Lead Clinical Candidate RXI-109 80 Mar 31, 2016: Rxi Pharmaceuticals Strengthens Intellectual Property Portfolio for Dermal Indications 81 Mar 28, 2016: RXi Pharmaceuticals to Present at the Oligonucleotide Therapeutics and Delivery Conference 82 Feb 16, 2016: Accel-Rx/BDC make second portfolio investment in ScarX Therapeutics 82 Oct 12, 2015: RXi Pharmaceuticals to Present at Premier Scientific Plastic Surgery Meeting 83 Oct 05, 2015: RXi Pharmaceuticals Bolsters Protection for its Novel Self-Delivering RNAi Platform with Notice of Allowance from USPTO 84 Sep 29, 2015: RXi Pharmaceuticals to Present at Dawson James Securities Growth Stock Conference 84 Sep 28, 2015: RXi Pharmaceuticals Granted Patent in China for Lead Clinical Candidate RXI-109 85 Jun 02, 2015: RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology 85 Mar 23, 2015: RXi Pharmaceuticals Reports Positive Advancements in its Dermatology Programs at the Occasion of the 73rd Annual Meeting of the American Academy of Dermatology 85 Dec 17, 2014: RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 87 Sep 29, 2014: RXi Pharmaceuticals to Present at the 13th Annual BIO Investor Forum 88 Appendix 89 Methodology 89 Coverage 89 Secondary Research 89 Primary Research 89 Expert Panel Validation 89 Contact Us 89 Disclaimer 90
List Of Tables
Number of Products under Development for Scar, H2 2016 10 Number of Products under Development for Scar - Comparative Analysis, H2 2016 11 Number of Products under Development by Companies, H2 2016 13 Number of Products under Investigation by Universities/Institutes, H2 2016 14 Comparative Analysis by Late Stage Development, H2 2016 15 Comparative Analysis by Clinical Stage Development, H2 2016 16 Comparative Analysis by Early Stage Development, H2 2016 17 Products under Development by Companies, H2 2016 18 Products under Investigation by Universities/Institutes, H2 2016 19 Scar - Pipeline by 3M Drug Delivery Systems, H2 2016 20 Scar - Pipeline by Albireo AB, H2 2016 21 Scar - Pipeline by Altacor Limited, H2 2016 22 Scar - Pipeline by Beech Tree Labs, Inc., H2 2016 23 Scar - Pipeline by Clanotech AB, H2 2016 24 Scar - Pipeline by Escape Therapeutics, Inc., H2 2016 25 Scar - Pipeline by FirstString Research, Inc., H2 2016 26 Scar - Pipeline by LegoChem Biosciences, Inc, H2 2016 27 Scar - Pipeline by Moerae Matrix, Inc., H2 2016 28 Scar - Pipeline by Promore Pharma, H2 2016 29 Scar - Pipeline by RXi Pharmaceuticals Corporation, H2 2016 30 Scar - Pipeline by VBS Pharmaceuticals, H2 2016 31 Assessment by Monotherapy Products, H2 2016 32 Number of Products by Stage and Target, H2 2016 34 Number of Products by Stage and Mechanism of Action, H2 2016 36 Number of Products by Stage and Route of Administration, H2 2016 38 Number of Products by Stage and Molecule Type, H2 2016 40 Scar - Dormant Projects, H2 2016 76 Scar - Discontinued Products, H2 2016 77
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.